EGFR and lung adenocarcinoma: Although the development of new diagnostic and therapeutic strategies has improved NSCLC treatment and led to longer survival rates, most treatable genetic mutations, such as those in the epidermal growth factor receptor (EGFR) family, anaplastic lymphoma kinase (ALK), and ROS Proto-oncogene 1 (ROS1), are more common in lung adenocarcinoma (LUAD) and are rarely observed in LUSC [3].